About Hyperfine Inc
- Industry: Health Care
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://hyperfinemri.com/
Frequently Asked Questions
What is the 52-week range for HYPR?
The 52-week high is $2.22 and the 52-week low is $0.7536.
What is the P/E ratio for HYPR?
The P/E ratio data is currently unavailable.
What is the dividend yield for HYPR?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -100.30%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -210.75%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.32.
Analyst Recommendation Trends
Wall Street analyst consensus for HYPR over the last few months:
Latest HYPR News
Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets
GUILFORD, Conn., September 28, 2026--Hyperfine appoints Roots Pharmaceutical as exclusive Swoop system distributor in the United Arab Emirates and Kuwait.
BTIG Reiterates Buy on Hyperfine, Maintains $2 Price Target
BTIG analyst Marie Thibault reiterates Hyperfine (NASDAQ:HYPR) with a Buy and maintains $2 price target.
MedtechWOMEN Names Hyperfine CEO Maria Sainz Winner of 2026 Ferolyn Powell Leadership Award
MENLO PARK, Calif., September 16, 2026--MedtechWOMEN today announced that Maria Sainz, President and CEO of Hyperfine, Inc., has been named the recipient of its 2026 Ferolyn Powell Leadership Award, and that Beverly Tang, co-founder and CEO of Starlight Cardiovascular, has received MedtechWOMEN’s first-ever Rising Star Award. Both leaders were recognized at the annual MedtechVISION Annual Conference at the Rosewood Sand Hill in Menlo Park, Calif.
Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents
GUILFORD, Conn., September 15, 2026--Completion of enrollment in study to support anticipated indication expansion for use of the Swoop® system with contrast agents.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-24 | TEISSEYRE THOMAS | -7,345 | $0.854 | $6,273 |
| 2026-08-24 | HALE BRETT | -7,345 | $0.854 | $6,273 |
| 2026-06-03 | Wolterman Dan | +52,600 | - | - |
| 2026-05-26 | HALE BRETT | -6,047 | $1.65 | $9,978 |
| 2026-05-26 | TEISSEYRE THOMAS | -6,047 | $1.65 | $9,978 |
| 2026-05-22 | Wolterman Dan | +157,700 | - | - |
| 2026-05-22 | Dahldorf John T | +157,700 | - | - |
| 2026-05-22 | Fattori Ruth A | +157,700 | - | - |
| 2026-05-22 | ROTHBERG JONATHAN M | +157,700 | - | - |
| 2026-03-31 | HALE BRETT | +330,000 | - | - |
| 2026-03-31 | TEISSEYRE THOMAS | +330,000 | - | - |
| 2026-03-31 | Sainz Maria | +750,000 | - | - |
| 2026-03-23 | TEISSEYRE THOMAS | -24,188 | $1.21 | $29,267 |
| 2026-03-23 | HALE BRETT | -24,188 | $1.21 | $29,267 |
| 2026-02-13 | TEISSEYRE THOMAS | -821 | $1.1115 | $913 |
| 2025-11-19 | TEISSEYRE THOMAS | -1,405 | $1.08 | $1,517 |